To evaluate the efficacy and safety of iNK cells infusion in patients with chronic active Epstein-Barr virus infection (CAEBV) and EBV-associated hemophagocytic lymphohistiocytosis (EBV-HLH) after allogeneic hematopoietic stem cell transplantation (allo-HSCT)
≤65 years，ECOG :0-2；
Cardiac EF≥40%, creatinine clearance ≥50%; aminotransferase（ALT/AST）<200U/L。；
In patients with HLH, HLH efficacy ≥Partial Response after prior treatment is required；
Estimated survival time is longer than three months；
Patients with evidence of grade II or more serious heart disease according to the New York Heart Association (NYHA) score (including Grade II) ; Clear diagnosis of cirrhosis；
Active infections other than EBV that have not yet been controlled；
Positive for hepatitis B virus or hepatitis C virus；
Active massive hemorrhage of internal organs (including gastrointestinal hemorrhage, alveolar hemorrhage, intracranial hemorrhage, etc.)；
Single group
NCR300（Allogenic Ipsc-derived Natural Killer cells ）
Other interventionPatients will receive iNK cells i.V. infusion at 1.0x10\^8/kg on days +14d, +21d, +28d, and +35d post-transplant. Continuation of the infusion after +35d post-transplant is at the discretion of the physician based on the patient's benefit.
Disease-free survival time (DFS)
Assessment of CAEBV, EBV-HLH systemic disease status and peripheral blood EBV-DNA levels
complete remission rate (CR)
EBV-DNA negative rate in relapsed/non-remitting patients
Recurrence rate (RT)
EBV-DNA reactivation rate for high-risk patients
cytomegalovirus DNA
Incidence of post-transplant infection-related comorbidities
Adverse Event（AE）
Assess the frequency and extent of adverse events
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
